lyophilized powder for solution for infusion
1000 mg
Trade name: Vancomycin, lyophilized powder for solution for infusion
1000 mg.
International non- proprietary name: Vancomycin.
Description: white to off- white or pinkish- white powder or porous mass.
Composition: each vial contains:
Active substance: vancomycin (as vancomycin hydrochloride)-1000 mg.
Pharmacotherapeutic group: Glycopeptide antibacterial agents.
ATC code: J01XA01.
Pharmacological properties:
Antibacterial agent having a bactericidal effect on the majority of microorganisms (acts bacteriostatically on enterococci).
Therapeutic indications
Vancomycin is indicated for the treatment of serious infections caused by susceptible strains of methicillin- resistant staphylococci. It is indicated in the following cases:
► for patients with allergic reactions to anti- bacterial agents from the group of penicillins;
► for patients who cannot be prescribed or who have not got a positive result after administration of other antibacterial agents, including penicillins or cephalosporins;
► for infections caused by vancomycin- susceptible organisms that are resistant to other antimicrobial agents.
Vancomycin is indicated for initial therapy of infections caused with high probability by methicillin – resistant staphylococci, but after receiving the results of studies of sensitivity to antibacterial agents the therapy should be adjusted accordingly.
Vancomycin is indicated for treatment of staphylococcal endocarditis. Its efficacy has been confirmed in treatment of infections caused by staphylococci, including septicaemia, bone infections, infections of the lower respiratory tract infections, infections of the skin and skin structure. If staphylococcal infections is purulent and localized, antibacterial agents are used as an adjunctive therapy to the appropriate surgical treatment.
There is an evidence that vancomycin is effective as monotherapy or in combination with aminoglycosides for treatment of endocarditis caused by Streptococcus viridans or S. bovis. For endocarditis caused by enterococci (e.g.E faecalis), vancomycin can be effective in combination with aminoglycosides only.
There is an evidence that vancomycin is effective for the treatment of diphtheroid endocarditis. Vancomycin is used in combination either with rifampicin or with aminoglycosides or rifampicin and aminoglycosides (e.g.in treatment of endocarditis emerged in the early period after valve replacement, caused by S epidermidis or diphtheroids).
Vancomycin for oral administration is used for treatment of pseudomembranous colitis caused by Clostridium difficile, and enterocolitis caused by Staphylococcus aureus.
Samples for bacteriological cultures should be obtained for the isolation and identification of pathogens, as well as for determination of their sensitivity to vancomycin.
In order to reduce the development of resistance and maintain the efficacy of vancomycin and other antibacterial agents, vancomycin should be used for treatment or prevention of infections caused by microorganisms with proven sensitivity to this agent. After receiving the results of studies of sensitivity to antibacterial agents the therapy should be adjusted accordingly. In the absence of the results of bacteriological studies, the data of local epidemiological studies are taken into account.
